Essential Pharma, a UK-based international specialty pharma group, announced on Thursday that it has completed two deals with United Kingdom-based Rosemont Pharmaceuticals, acompany focused on manufacturing oral liquid products.

Essential Pharma has completed the divestment of its oral liquid portfolio to Rosemont. Essential has separately acquired a series of products with geographic expansion potential.

According to the terms of the divestment, Rosemont Pharmaceuticals is acquiring the product portfolio of licences, registrations and trademarks, and related commercial rights, to various oral generic products that are used to treat a range of conditions in various therapeutic areas.